Privacy & Other Trust Info Other Name(s): Alfacalcidol: 1-alpha-hydroxycholecalciferol, 1-alpha-hydroxycholécalciférol, 1 alpha (OH)D3. Calcifediol: 25-HCC, 25-hydroxycholecalciferol, 25-hydroxycholécalciferol , 25-hydroxyvitamin D3, 25-hydroxyvitamine D3, 25-OHCC, 25-OHD3, Calcifédiol. ...
(HCC) who have not received prior systemic therapy; in combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma as determined by an FDA-approved test; and for the treatment of adult patients with unresectable...
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data described inWARNINGS AND ...
The data described in the WARNINGS AND PRECAUTIONS section and below reflect exposure to CABOMETYX: as a single agent in 409 patients with RCC enrolled in randomized, active-controlled trials (CABOSUN, METEOR), 467 patients with HCC enrolled in a randomized, placebo-controlled trial (CELESTIAL), ...
The efficacy of IMFINZI in combination with tremelimumab-actl was evaluated in the HIMALAYA study (NCT03298451), a randomized (1:1:1), open-label, multicenter study in patients with confirmed uHCC who had not received prior systemic treatment for HCC. Patients were randomized to one of two in...